WPI Venture Forum Presents Corporat
Boston Scientific with James Barry, PhD
FOR IMMEDIATE RELEASE/
Contact: WPI Venture Forum, +1-508-831-5075
Tuesday, September 14, 2004, 6-9 p.m.
Worcester Polytechnic Institute, Campus Center Odeum
WORCESTER, MA - August 23, 2004 - James Barry, PhD, Corporate Vice President of Research and Development at Boston Scientific, Inc., will lead off the new season at the WPI Venture Forum. Dr. Barry will maintain a fairly technical slant to his presentation as he leads the audience on a virtual tour of the company's trials and tribulations of its seven years of development. According to Dr. Barry, "I will, for relevance, try to weave in the challenges/decisions that the entrepreneur might have to grapple with, particularly in a start-up like environment."
Dr. Barry joined Boston Scientific in 1992 and is responsible for the company's corporate research and development function, which includes the development of drug/device combination technologies including implant and catheter-based delivery systems. Under his leadership, Boston Scientific has developed a paclitaxel-eluting stent technology that is designed to reduce the rate of restenosis in angioplasty patients.
Before joining Boston Scientific, Dr. Barry worked in the Howmedica Division of Pfizer Hospital Products Group as a principal research scientist. Prior to that, he worked with Kontron Instruments, Inc.
Case Presentation: DecImmune Therpeutics
Following Dr. Barry, the case presentation will be Richard Foemmel, PhD, President and CEO, of DecImmune Therapeutics, Inc. (Boston, MA), an early stage biotechnology company developing products for inflammation and autoimmunity based on natural antibody targets. Based on more than 10 years of research at the Center for Blood Research (CBR) Institute and Brigham & Women's Hospital, DecImmune's founding scientists have discovered the mechanism by which natural antibodies initiate and regulate the immune system in various diseases. In its first clinical indication, the company is developing compounds to prevent inflammation due to reperfusion injury in cardiovascular disease.
A panel of three experts will evaluate the case presenter's written business plan and live presentation: Ed Cannon, PhD, founder, President, and CEO of Elixir Pharmaceuticals; Eileen Heffernan, formerly of Aquila Biopharmaceuticals; and Monica Vnuk, MD, an associate with Oxford Bioscience Partners.
The WPI Venture Forum meeting will be held on Tuesday, September 14, 2004, at the Odeum Campus Center on the WPI campus in Worcester, MA. Registration begins at 6:00 p.m. and the meeting begins at 6:30 p.m. Registration cost is $10 individual, annual and lifetime members; and $20 nonmembers.
About the WPI Venture Forum
The WPI Venture Forum was created in 1990 to promote the entrepreneurial spirit and to serve those who engage in technology- based entrepreneurial enterprises by providing advice, support and education tailored to meet their needs. The forum fosters entrepreneurship through such activities as monthly programs, a business plan contest, a weekly radio show on News Radio WTAG (Saturdays, 5-7 pm, 580am), and a monthly newsletter.
The Venture Forum, as part of the Collaborative for Entrepreneurship & Innovation in the Department of Management at WPI, serves individuals who are seeking to begin their own technology-based businesses; founders, presidents, and senior managers of start-up or early-stage companies; senior managers of companies that are restarting or making a transition for one mode of operation to another; and employees leaving large companies due to a reduction in force or to start businesses.